Literature DB >> 24182551

Chronic thromboembolic pulmonary hypertension-associated dysfibrinogenemias exhibit disorganized fibrin structure.

James J Marsh1, Peter G Chiles, Ni-Cheng Liang, Timothy A Morris.   

Abstract

INTRODUCTION: Mechanisms contributing to the pathogenesis of chronic thromboembolic pulmonary hypertension (CTEPH) are poorly understood. This disorder is characterized by incomplete resolution of pulmonary perfusion defects resulting from acute venous thromboembolism. We previously identified several dysfibrinogenemias in some patients with CTEPH. The purpose of this study was to determine whether fibrin clot architecture might be implicated in the thrombolytic resistance in patients with these CTEPH-associated dysfibrinogenemias.
MATERIALS AND METHODS: Purified fibrinogen from patients and healthy controls was clotted with thrombin in the presence of calcium. Clot turbidity, porosity, and susceptibility to fibrinolysis were evaluated by spectrophotometric and permeation analyses. Fibrin network structure was assessed by laser-scanning confocal microscopy.
RESULTS: Compared to normal fibrinogen, CTEPH-associated dysfibrinogenemias exhibited low clot turbidity, decreased porosity, and fibrinolytic resistance. In addition, the dysfibrinogenemias exhibited a more disorganized fibrin network structure characterized by thinner fibers, greater network dispersal and more extensive fiber branching.
CONCLUSIONS: Abnormal clot architecture and fibrinolytic resistance may contribute to incomplete clot resolution following acute venous thromboembolism in patients with CTEPH-associated dyfibrinogenemia.
© 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CTEPH; CTVD; Confocal microscopy; Fibrinogen; Fibrinolysis; Pulmonary embolism; Thrombosis; chronic thromboembolic pulmonary hypertension; chronic thrombotic venous disease

Mesh:

Substances:

Year:  2013        PMID: 24182551     DOI: 10.1016/j.thromres.2013.09.024

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  8 in total

1.  The connection between pulmonary embolism and chronic thromboembolic pulmonary hypertension: research session at the American Thoracic Society 2016 Meeting.

Authors:  Timothy Morris
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

2.  Novel venous thromboembolism mouse model to evaluate the role of complete and partial factor XIII deficiency in pulmonary embolism risk.

Authors:  Sravya Kattula; Yaqiu Sang; Gustaaf de Ridder; Anna C Silver; Emma G Bouck; Brian C Cooley; Alisa S Wolberg
Journal:  J Thromb Haemost       Date:  2021-09-06       Impact factor: 5.824

Review 3.  Fibrinogen and Factor XIII in Venous Thrombosis and Thrombus Stability.

Authors:  Alisa S Wolberg; Yaqiu Sang
Journal:  Arterioscler Thromb Vasc Biol       Date:  2022-06-02       Impact factor: 10.514

Review 4.  Current concepts in the pathogenesis of chronic thromboembolic pulmonary hypertension.

Authors:  Daniel T Matthews; Anna R Hemnes
Journal:  Pulm Circ       Date:  2016-06       Impact factor: 3.017

5.  Outcomes of Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension at a Single Center in Taiwan.

Authors:  Yu-Jhou Chen; Chien-Te Ho; Feng-Chun Tsai; Chia-Pin Lin; Lung-An Hsu; Chun-Li Wang; Kuang-Tso Lee; Wan-Jing Ho
Journal:  Acta Cardiol Sin       Date:  2019-03       Impact factor: 2.672

Review 6.  Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment.

Authors:  Mark Toshner; Joanna Pepke-Zaba
Journal:  F1000Prime Rep       Date:  2014-06-02

Review 7.  Prothrombotic Fibrin Clot Phenotype in Patients with Deep Vein Thrombosis and Pulmonary Embolism: A New Risk Factor for Recurrence.

Authors:  Anetta Undas
Journal:  Biomed Res Int       Date:  2017-06-27       Impact factor: 3.411

8.  Fibrinogen and the prediction of residual obstruction manifested after pulmonary embolism treatment.

Authors:  Benjamin Planquette; Olivier Sanchez; James J Marsh; Peter G Chiles; Joseph Emmerich; Grégoire Le Gal; Guy Meyer; Tanya Wolfson; Anthony C Gamst; Roger E Moore; Gabriel B Gugiu; Timothy A Morris
Journal:  Eur Respir J       Date:  2018-11-15       Impact factor: 33.795

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.